>Anti-obesity drugs are all the rage. We are constantly hearing about Ozempic, Wegovy, or Zepbound. The chemical compound in the anti-obesity drugs is known as GLP-1 or glucagon-like peptide. Currently, Eli Lilly & Co (
LLY) and Novo Nordisk (
NVO) are the two main players in an industry that, according to Bloomberg reporting, Goldman Sachs expects to reach $130 billion by 2030. This is an increase from $6 billion in 2023. However, there are at least eight prescription drugs approved for weight loss and others are in clinical trials.>Last week Viking Therapeutics (
VKTX) added some spice to the industry by moving its anti-obesity drug to Phase 3 development. Viking Therapeutics is not profitable and sports a total market cap of just $8 billion. It can be considered David when compared to the Goliath, Eli Lilly (
LLY), which has a current market cap of $740 billion. Nonetheless, Eli Lilly's market value contracted by $120 billion amid the trial success reported by Viking Therapeutics. How does an investor gain exposure to this booming industry without assuming the risk of investing in a single pharmaceutical company? A viable option is through the use of exchange traded funds.>There is a relatively new ETF the Roundhill GLP-1 & Weight Loss ETF trading under the ticker OZEM. It sports a reasonable expense ratio of 0.59% as the trade-off to gain direct exposure to the world's most promising weight loss companies. Tema, a company managing a different ETF (
HRTS) in this space, puts the industry value as high as $1 trillion. HRTS could be used as another ETF option, but bear in mind that it has a significantly higher Gross Expense Ratio at 0.99%. It is also less concentrated in today's major players, Eli Lilly and Novo Nordisk, with a combined 9.4% exposure.
How does an investor know when a new pharmaceutical product will affect an established product on the market? It is difficult to track U.S. Food and Drug Administration (FDA) approvals, but FDA trial news is often the first tip-off for retail investors. A retail investor, though, does not need to be an industry insider, or necessarily understand the science of each chemical compound, to gain exposure to the long-term secular trend in anti-obesity drugs. Prescription drugs, though, do eventually lose their exclusive patents and become subject to generic competition, which will adversely impact sales and potential profitability. The ETF channel helps mitigate that life cycle risk because diversification is inherent in its structure. These are early days still in the anti-obesity drug phenomenon. Eli Lilly and Novo Nordisk are the industry stalwarts. One can gain a healthy level of exposure to both (38%), along with the ability to own a large swath of this booming market, with an investment in the Roundhill GLP-1 & Weight Loss ETF (OZEM).